All News

pregnancy,doctor,consult

Pregnancy in SLE: Risks Extend Beyond Clinical Concerns

Bella Mehta, MBBS, MS

While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes.

Read Article
light bulb idea

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases

Md Yuzaiful Md Yusof, MRCP(UK), PhD

During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.

Read Article
Lung,AI,Pleura

A new mechanism of action in SARD-ILD

Aurelie Najm, MD, PhD

Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases.

Read Article
eular

EULAR 2025 – Day 4 Report

Jack Cush, MD

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article
smartphone

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia

Antoni Chan, MD, PhD

The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence and digital health technologies. At #EULAR2025, the Bechterew-App Trial (LB0002) presented important new data on Axia, a novel AI-powered digital therapeutic developed for axSpA.

Read Article
EULAR 2025 – Day 4 Report Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR

Links:

Dr. John Cush RheumNow ( View Tweet)
Which CAR T Cell is Mighty? Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd
Dr. John Cush RheumNow ( View Tweet)
EULAR Daily Recap: Day 1 and 2 LIVE Daily Recap Day 1 & 2 – EULAR 2025 Coverage brings you the latest updates from EULAR 2025. Join Dr. Jack Cush, Dr. Mrinalini Dey, Dr. Antoni Chan, and Dr. Nelly Ziade as they discuss the biggest breakthroughs, standout sessions, and expert https://t.co/vkTo2MchsC
Dr. John Cush RheumNow ( View Tweet)
Seronegative Arthritis Breakthroughs Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb
Dr. John Cush RheumNow ( View Tweet)
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 https://t.co/jPAai9FLkb
Dr. John Cush RheumNow ( View Tweet)
Sonelokimab in PsA Dr. Adela Castro reports on OP0096, 'Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial,' https://t.co/KmV6Rx4uFT
Dr. John Cush RheumNow ( View Tweet)
Health inequities in rheumatology: A central theme This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush RheumNow ( View Tweet)
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu
Dr. John Cush RheumNow ( View Tweet)
Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/kJk1R8ubqk
Dr. John Cush RheumNow ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×